Crisanta (Yasmin)3 0.03mg

USD $19.99

Each Crisanta contains 21 pills of Drospirenone & Ethinel Estradiol hormone. It is used as a birth control for women and for treating acne in females.

ATC Classification: G03AA12
Active Ingrediant: Drospirenone & Ethinel Estradiol
Generic Name: Crisanta
Manufacturer: Cipla Limited
Strength: 3 0.03mg
Dosage Type: Tablet
Packaging Type: Blister in Box
Contains: 21 Tab

Important update for customers in the USA:

The World has stopped all packages mailing to the USA due to De Minimus Exemption.

  1. This situation is real and affects the world, not just India. See your local news or this Fox Business report .
  2. We got through COVID; we will get through this as well.
  3. By law we must temporarily remove Card and eCheck for USA shipments because we cannot mail today.
  4. Suggestion: order now to hold your place — shipping will be first-come, first-served once mailing resumes (mail is already queued).
  5. Waiting to place your order is fine; we expect resolution soon, but mail is piling up worldwide, not only with our firm.
  6. We ship normally to the UK, AUS, Japan, and most others. The hold is on the USA side only.
Thanks for your patience.
Examples of Packages sent

Medication Safety Issues

Sound-alike/look-alike issues:

Yaz may be confused with Beyaz, Yasmin

 

Storage/Stability

Store at 25?C (77?F); excursions permitted to 15?C to 30?C (59?F to 86?F).

 

Adverse Reactions

Frequency not defined. Reactions listed are based on reports for other agents in this same pharmacologic class (oral contraceptives) and may not be specifically reported for drospirenone/ethinyl estradiol.

Increased risk or evidence of association with use:

Cardiovascular: Arterial thromboembolism, cerebral thrombosis, hypertension, local thrombophlebitis, mesenteric thrombosis, myocardial infarction, pulmonary embolism, retinal thrombosis

Central nervous system: Cerebral hemorrhage

Gastrointestinal: Gallbladder disease

Hepatic: Hepatic adenoma, hepatic neoplasm (benign)

Adverse reactions considered drug related:

Cardiovascular: Edema, worsening of varicose veins

Central nervous system: Depression, exacerbation of tics, migraine

Dermatologic: Allergic skin rash, chloasma

Endocrine & metabolic: Amenorrhea, breast changes (breast hypertrophy, breast secretion, breast tenderness, mastalgia), decreased serum folate level, exacerbation of porphyria, menstrual disease (menstrual flow changes), weight changes

Gastrointestinal: Abdominal cramps, bloating, carbohydrate intolerance, nausea, vomiting

Genitourinary: Breakthrough bleeding, cervical ectropion, cervical erosion, change in cervical secretions, decreased lactation (with use immediately postpartum), infertility (temporary), spotting, vulvovaginal candidiasis

Hepatic: Cholestatic jaundice

Hypersensitivity: Anaphylaxis/anaphylactoid reaction (including angioedema, circulatory shock, respiratory collapse, urticaria)

Neuromuscular & skeletal: Exacerbation of systemic lupus erythematosus

Ophthalmic: Change in corneal curvature (steepening), contact lens intolerance

Adverse reactions in which association is not confirmed or denied:

Cardiovascular: Budd-Chiari syndrome

Central nervous system: Dizziness, headache, nervousness

Dermatologic: Acne vulgaris, erythema multiforme, erythema nodosum, loss of scalp hair

Endocrine & metabolic: Change in libido, hirsutism, porphyria, premenstrual syndrome

Gastrointestinal: Change in appetite, colitis, pancreatitis

Genitourinary: Cystitis-like syndrome, dysmenorrhea, vaginitis

Hematologic & oncologic: Hemolytic-uremic syndrome, hemorrhagic eruption

Ophthalmic: Cataract, optic neuritis (with or without partial or complete loss of vision)

Renal: Renal insufficiency

Additional information

Active Ingrediant

Generic Name

Alternate Names

, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Strength

Dosage Type

Packaging Type

Brand

Cipla

Reviews

There are no reviews yet

Be the first to review “Crisanta (Yasmin)3 0.03mg”

Your email address will not be published. Required fields are marked *